nach oben

Erschienen in:

01.02.2015 | Original Article

Enhanced human mesenchymal stem cell survival under oxidative stress by overexpression of secreted frizzled-related protein 2 gene

verfasst von: Kanjana Pomduk, Pakpoom Kheolamai, Yaowalak U-Pratya, Methichit Wattanapanitch, Nuttha Klincumhom, Surapol Issaragrisil

Erschienen in: Annals of Hematology | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Human mesenchymal stem cells (hMSCs) have been used to improve engraftment and to treat graft versus host disease following allogeneic hematopoietic stem cell transplantation. However, oxidative stress presented in the microenvironment can damage the transplanted hMSCs and therefore reduce their survival in target organs. We investigated how to enhance the survival of hMSCs under oxidative stress by overexpressing secreted frizzled-related protein 2 (sFRP2) gene in bone marrow-derived hMSCs and umbilical cord-derived hMSCs. The survival and characteristics of those sFRP2-overexpressing hMSCs (sFRP2-BM-hMSCs and sFRP2-UC-hMSCs) were studied compared with non-transduced hMSCs. We found that the percentages of viable cells in culture of sFRP2-BM-hMSCs and sFRP2-UC-hMSCs in the absence or presence of 0.75 mM H₂O₂ were significantly higher than those of their non-transduced counterparts. The overexpression of sFRP2 gene did not affect the characteristics of hMSCs regarding their morphology, surface marker expression, and differentiation potential. Our study suggests that overexpression of sFRP2 gene in hMSCs might improve the therapeutic effectiveness of hMSC transplantation.

Nur mit Berechtigung zugänglich

Salem HK, Thiemermann C (2010) Mesenchymal stromal cells: current understanding and clinical status. Stem Cells 28:585–596PubMedCentralPubMed

Zuk PA, Zhu M, Ashjian P et al (2002) Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 13:4279–4295PubMedCentralPubMedCrossRef

Diaz-Prado S, Muinos-Lopez E, Hermida-Gomez T et al (2010) Multilineage differentiation potential of cells isolated from the human amniotic membrane. J Cell Biochem 111:846–857PubMedCrossRef

Hass R, Kasper C, Bohm S, Jacobs R (2011) Different populations and sources of human mesenchymal stem cells (MSC): a comparison of adult and neonatal tissue-derived MSC. Cell Commun Signal 9:12PubMedCentralPubMedCrossRef

Wang HS, Hung SC, Peng ST et al (2004) Mesenchymal stem cells in the Wharton’s jelly of the human umbilical cord. Stem Cells 22:1330–1337PubMedCrossRef

Dominici M, Le Blanc K, Mueller I et al (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8:315–317PubMedCrossRef

Bianco P, Riminucci M, Gronthos S, Robey PG (2001) Bone marrow stromal stem cells: nature, biology, and potential applications. Stem Cells 19:180–192PubMedCrossRef

Bartholomew A, Sturgeon C, Siatskas M et al (2002) Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 30:42–48PubMedCrossRef

Benvenuto F, Ferrari S, Gerdoni E et al (2007) Human mesenchymal stem cells promote survival of T cells in a quiescent state. Stem Cells 25:1753–1760PubMedCrossRef

10.

Choi M, Lee HS, Naidansaren P et al (2013) Proangiogenic features of Wharton’s jelly-derived mesenchymal stromal/stem cells and their ability to form functional vessels. Int J Biochem Cell Biol 45:560–570PubMedCrossRef

11.

Glennie S, Soeiro I, Dyson PJ et al (2005) Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 105:2821–2827PubMedCrossRef

12.

Roubelakis MG, Tsaknakis G, Pappa KI et al (2013) Spindle shaped human mesenchymal stem/stromal cells from amniotic fluid promote neovascularization. PLoS One 8:e54747PubMedCentralPubMedCrossRef

13.

Jiang XX, Zhang Y, Liu B et al (2005) Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 105:4120–4126PubMedCrossRef

14.

Krampera M, Glennie S, Dyson J et al (2003) Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 101:3722–3729PubMedCrossRef

15.

Shi M, Liu ZW, Wang FS (2011) Immunomodulatory properties and therapeutic application of mesenchymal stem cells. Clin Exp Immunol 164:1–8PubMedCentralPubMedCrossRef

16.

Carrancio S, Romo C, Ramos T et al (2013) Effects of MSC coadministration and route of delivery on cord blood hematopoietic stem cell engraftment. Cell Transplant 22:1171–1183PubMedCrossRef

17.

Macmillan ML, Blazar BR, DeFor TE, Wagner JE (2009) Transplantation of ex-vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: results of a phase I–II clinical trial. Bone Marrow Transplant 43:447–454PubMedCrossRef

18.

Meuleman N, Tondreau T, Ahmad I et al (2009) Infusion of mesenchymal stromal cells can aid hematopoietic recovery following allogeneic hematopoietic stem cell myeloablative transplant: a pilot study. Stem Cells Dev 18:1247–1252PubMedCrossRef

19.

Fang B, Song Y, Liao L et al (2007) Favorable response to human adipose tissue-derived mesenchymal stem cells in steroid-refractory acute graft-versus-host disease. Transplant Proc 39:3358–3362PubMedCrossRef

20.

Kebriaei P, Isola L, Bahceci E et al (2009) Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol Blood Marrow Transpl 15:804–811CrossRef

21.

Muroi K, Miyamura K, Ohashi K et al (2013) Unrelated allogeneic bone marrow-derived mesenchymal stem cells for steroid-refractory acute graft-versus-host disease: a phase I/II study. Int J Hematol 98:206–213PubMedCrossRef

22.

Perez-Simon JA, Lopez-Villar O, Andreu EJ et al (2011) Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: results of a phase I/II clinical trial. Haematologica 96:1072–1076PubMedCentralPubMedCrossRef

23.

Ringden O, Uzunel M, Rasmusson I et al (2006) Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 81:1390–1397PubMedCrossRef

24.

von Bonin M, Stolzel F, Goedecke A et al (2009) Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant 43:245–251CrossRef

25.

Haider H, Ashraf M (2008) Strategies to promote donor cell survival: combining preconditioning approach with stem cell transplantation. J Mol Cell Cardiol 45:554–566PubMedCentralPubMedCrossRef

26.

Toma C, Pittenger MF, Cahill KS et al (2002) Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 105:93–98PubMedCrossRef

27.

Aiello S, Cassis P, Mister M et al (2011) Rabbit anti-rat thymocyte immunoglobulin preserves renal function during ischemia/reperfusion injury in rat kidney transplantation. Transpl Int 24:829–838PubMedCrossRef

28.

Danilovic A, Lucon AM, Srougi M et al (2011) Protective effect of N-acetylcysteine on early outcomes of deceased renal transplantation. Transplant Proc 43:1443–1449PubMedCrossRef

29.

Czubkowski P, Socha P, Pawlowska J (2011) Oxidative stress in liver transplant recipients. Ann Transpl 16:99–108

30.

Tain YL, Muller V, Szabo A et al (2006) Lack of long-term protective effect of antioxidant/anti-inflammatory therapy in transplant-induced ischemia/reperfusion injury. Am J Nephrol 26:213–217PubMedCentralPubMedCrossRef

31.

Robey TE, Saiget MK, Reinecke H, Murry CE (2008) Systems approaches to preventing transplanted cell death in cardiac repair. J Mol Cell Cardiol 45:567–581PubMedCentralPubMedCrossRef

32.

Leyns L, Bouwmeester T, Kim SH et al (1997) Frzb-1 is a secreted antagonist of Wnt signaling expressed in the Spemann organizer. Cell 88:747–756PubMedCentralPubMedCrossRef

33.

Lin K, Wang S, Julius MA et al (1997) The cysteine-rich frizzled domain of Frzb-1 is required and sufficient for modulation of Wnt signaling. Proc Natl Acad Sci U S A 94:11196–11200PubMedCentralPubMedCrossRef

34.

Wang S, Krinks M, Lin K et al (1997) Frzb, a secreted protein expressed in the Spemann organizer, binds and inhibits Wnt-8. Cell 88:757–766PubMedCrossRef

35.

Mirotsou M, Zhang Z, Deb A et al (2007) Secreted frizzled related protein 2 (Sfrp2) is the key Akt-mesenchymal stem cell-released paracrine factor mediating myocardial survival and repair. Proc Natl Acad Sci U S A 104:1643–1648PubMedCentralPubMedCrossRef

36.

Alfaro MP, Pagni M, Vincent A et al (2008) The Wnt modulator sFRP2 enhances mesenchymal stem cell engraftment, granulation tissue formation and myocardial repair. Proc Natl Acad Sci U S A 105:18366–18371PubMedCentralPubMedCrossRef

37.

Zhang Z, Deb A, Zhang Z et al (2009) Secreted frizzled related protein 2 protects cells from apoptosis by blocking the effect of canonical Wnt3a. J Mol Cell Cardiol 46:370–377PubMedCentralPubMedCrossRef

38.

Alfaro MP, Vincent A, Saraswati S et al (2010) sFRP2 suppression of bone morphogenic protein (BMP) and Wnt signaling mediates mesenchymal stem cell (MSC) self-renewal promoting engraftment and myocardial repair. J Biol Chem 285:35645–35653PubMedCentralPubMedCrossRef

Titel: Enhanced human mesenchymal stem cell survival under oxidative stress by overexpression of secreted frizzled-related protein 2 gene
verfasst von: Kanjana Pomduk
Pakpoom Kheolamai
Yaowalak U-Pratya
Methichit Wattanapanitch
Nuttha Klincumhom
Surapol Issaragrisil
Publikationsdatum: 01.02.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: Annals of Hematology / Ausgabe 2/2015
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-014-2210-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2015

A patient diagnosed with BRAF-mutated non-small cell lung cancer and hairy cell leukemia: at last, which entity is really carrying the BRAF mutation?

DNA topoisomerase IIβ as a molecular switch in neural differentiation of mesenchymal stem cells

Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes

Extensive toxic epidermal necrolysis following brentuximab vedotin administration

Chronic hepatitis E virus infection following allogeneic hematopoietic stem cell transplantation: an important differential diagnosis for graft versus host disease

Platelet fluctuations during thrombopoietin-receptor agonist treatment: correlation with platelet apoptosis